drugset / Trial / NCT00384956
A Phase II Study of Intravenous Azacitidine Alone in Patients With Myelodysplastic Syndromes
NaSingle-groupOpen-labelTreatment
Summary
The primary endpoint of this study is to estimate morphologic complete remission rate. Estimation of response rate is also a secondary objection.
Timeline
- Start
- 2006-08
- Primary completion
- 2008-08
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Azacitidine | Other / unclassified | 100 mg/m2 | Intravenous |